Roxithromycin: Difference between revisions
Disambiguate Plasma to Blood plasma using popups |
|||
| Line 25: | Line 25: | ||
German pharmaceutical company [[Hoechst AG|Hoechst Uclaf]] brought out roxithromycin in [[1987]]. |
German pharmaceutical company [[Hoechst AG|Hoechst Uclaf]] brought out roxithromycin in [[1987]]. |
||
== Available forms == |
== Available forms == |
||
Roxithromycin is commonly |
Roxithromycin is commonly available as tablets or oral suspension. |
||
== Mechanism of action == |
== Mechanism of action == |
||
Roxithromycin prevents [[bacterium|bacteria]] from growing, by interfering with their [[protein synthesis]]. Roxithromycin binds to the subunit 50S of the bacterial [[ribosome]], and thus inhibits the translocation of [[peptide]]s. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly ''[[Legionella pneumophila]]''. |
Roxithromycin prevents [[bacterium|bacteria]] from growing, by interfering with their [[protein synthesis]]. Roxithromycin binds to the subunit 50S of the bacterial [[ribosome]], and thus inhibits the translocation of [[peptide]]s. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly ''[[Legionella pneumophila]]''. |
||
Revision as of 06:11, 30 November 2006
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| ATC code | |
| Pharmacokinetic data | |
| Metabolism | Liver |
| Elimination half-life | 12 hours |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.121.308 |
| Chemical and physical data | |
| Formula | C41H76N2O15 |
| Molar mass | 837.047 g/mol |
Roxithromycin is a semi-synthetic macrolide antibiotic. It is used to treat respiratory tract, urinary and soft tissue infections. Roxithromycin is derived from erythromycin, containing the same 14-membered lactone ring. However, an N-oxime side chain is attached to the lactone ring.
Roxithromycin is available under several brandnames, for example Surlid, Rulide, Biaxsig, Roxar and Roximycin.
History
German pharmaceutical company Hoechst Uclaf brought out roxithromycin in 1987.
Available forms
Roxithromycin is commonly available as tablets or oral suspension.
Mechanism of action
Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly Legionella pneumophila.
Pharmacokinetics
When taken before a meal, roxithromycin is very rapidly absorbed, and diffused into most tissues and phagocytes. Due to the high concentration in phagocytes, roxithromycin is actively transported to the site of infection. During active phagocytosis, large concentrations of roxithromycin are released.
Metabolism
Only a small portion of roxithromycin is metabolised. Most of roxithromycin is secreted unchanged into the bile and some in expired air. Under 10% is excreted into the urine. Roxithromycin's half-life is 12 hours.
Side effects
Most common side effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side effects include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste.
Drug interactions
Roxithromycin has less interactions than erythromycin as it has a lower affinity for cytochrome P450.
Roxithromycin does not interact with oral contraceptives, prednisolone, carbamazepine, ranitidine or antacids.
When roxithromycin is administered with theophylline, some studies have shown an increase in the plasma concentration of theophylline. A change in dosage is usually not required but patients with high levels of theophylline at the start of the treatment should have their plasma levels monitored.
Roxithromycin appears to interact with warfarin. This is shown by an increase in prothrombin time (international normalised ratio (INR)) in patients taking roxithromycin and warfarin concurrently. As a consequence, severe bleeding episodes have occurred.